| RAS-targeted therapies: is the undruggable drugged? AR Moore, SC Rosenberg, F McCormick, S Malek Nature reviews Drug discovery 19 (8), 533-552, 2020 | 937 | 2020 |
| Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma AR Moore, E Ceraudo, JJ Sher, Y Guan, AN Shoushtari, MT Chang, ... Nature genetics 48 (6), 675-680, 2016 | 341 | 2016 |
| Spliceosomal disruption of the non-canonical BAF complex in cancer D Inoue, GL Chew, B Liu, BC Michel, J Pangallo, AR D’Avino, T Hitchman, ... Nature 574 (7778), 432-436, 2019 | 210 | 2019 |
| ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma I Yen, F Shanahan, J Lee, YS Hong, SJ Shin, AR Moore, J Sudhamsu, ... Nature 594 (7863), 418-423, 2021 | 93 | 2021 |
| GNA11 Q209L mouse model reveals RasGRP3 as an essential signaling node in uveal melanoma AR Moore, L Ran, Y Guan, JJ Sher, TD Hitchman, JQ Zhang, C Hwang, ... Cell reports 22 (9), 2455-2468, 2018 | 88 | 2018 |
| Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma TD Hitchman, G Bayshtok, E Ceraudo, AR Moore, C Lee, R Jia, N Wang, ... Clinical Cancer Research 27 (5), 1476-1490, 2021 | 45 | 2021 |
| Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signaling E Ceraudo, M Horioka, JM Mattheisen, TD Hitchman, AR Moore, ... Journal of Biological Chemistry 296, 2021 | 38 | 2021 |
| A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon D Gao, Y Zhan, W Di, AR Moore, JJ Sher, Y Guan, S Wang, Z Zhang, ... PLoS One 11 (8), e0161084, 2016 | 26 | 2016 |
| Author Correction: RAS-targeted therapies: is the undruggable drugged? AR Moore, SC Rosenberg, F McCormick, S Malek Nature Reviews Drug Discovery 19 (12), 902-902, 2020 | 20 | 2020 |
| The promise and peril of KRAS G12C inhibitors AR Moore, S Malek Cancer Cell 39 (8), 1059-1061, 2021 | 18 | 2021 |
| ETV4 mediates dosage-dependent prostate tumor initiation and cooperates with p53 loss to generate prostate cancer D Li, Y Zhan, N Wang, F Tang, CJ Lee, G Bayshtok, AR Moore, ... Science Advances 9 (14), eadc9446, 2023 | 10 | 2023 |
| Uveal Melanoma Oncogene CYSLTR2 Encodes a Constitutively Active GPCR Highly Biased Toward Gq Signaling E Ceraudo, M Horioka, JM Mattheisen, TD Hitchman, AR Moore, ... BioRxiv, 663153, 2019 | 10 | 2019 |
| RAS-targeted therapies AR Moore, SC Rosenberg, F McCormick, S Malek Nature Reviews Drug Discovery, 1-1, 2021 | 1 | 2021 |
| Abstract A039: RAS signaling strength determines phenotypic response in the colon AR Moore, SM Carlos, EE Storm, LM McGinnis, S Malek, FJ de Sauvage Molecular Cancer Research 21 (5_Supplement), A039-A039, 2023 | | 2023 |
| RAS-mutant mouse models confirm tissue-specificity and reveal unique oncogenic activity of KrasQ61R AR Moore, J Liang, R Piskol, L McGinnis, DS Kirkpatrick, S Malek Cancer Research 81 (13_Supplement), 2923-2923, 2021 | | 2021 |
| RAS-targeted therapies: is the undruggable drugged?(vol 19, pg 533, 2020) AR Moore, SC Rosenberg, F McCormick, S Malek Nature Reviews Drug Discovery 19 (12), 902-902, 2020 | | 2020 |
| Abstract A07: Activating mutations in uveal melanoma convey sensitivity to g-alpha q inhibition TD Hitchman, E Ceraudo, AR Moore, AN Shoushtari, JH Francis, Y Guan, ... Cancer Research 80 (19_Supplement), A07-A07, 2020 | | 2020 |
| Activating mutations in uveal melanoma convey sensitivity to g-alpha q inhibition. TD Hitchman, E Ceraudo, AR Moore, AN Shoushtari, JH Francis, Y Guan, ... CANCER RESEARCH 80 (19), 35-35, 2020 | | 2020 |
| Nongenomic BAP1 aberrancy drives highly aggressive cutaneous melanoma phenotype. H Zhu, J Oba, X Yu, CA Creasy, MA Forget, F Carapeto, CL Haymaker, ... CANCER RESEARCH 80 (19), 24-25, 2020 | | 2020 |
| Abstract PR03: Nongenomic BAP1 aberrancy drives highly aggressive cutaneous melanoma phenotype H Zhu, J Oba, X Yu, CA Creasy, MA Forget, F Carapeto, CL Haymaker, ... Cancer Research 80 (19_Supplement), PR03-PR03, 2020 | | 2020 |
